✦ LIBER ✦

1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885

✍ Scribed by Lawitz, E.; Gruener, D.; Hill, J.; Marbury, T.; Komjathy, S.; DeMicco, M.; Murillo, A.; Jenkin, F.; Kim, K.; Simpson, J.; Aycock, M.; Mathias, A.; Yang, C.; Dowdy, E.; Liles, M.; Cheng, G.; Mondou, E.; Link, J.; Brainard, D.; McHutchison, J.; Ohmstede, C.; Bannister, R.

Book ID: 122677164
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 192 KB
Volume: 54
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(11)61221-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

✍ Lawitz, E.J.; Marbury, T.C.; Vince, B.D.; Grunenberg, N.; Rodriguez-Torres, M.; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 71 KB

1172 ANTIVIRAL ACTIVITY AND RESISTANCE P

1172 ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885

✍ Cheng, G.; Peng, B.; Corsa, A.; Yu, M.; Nash, M.; Lee, Y.-J.; Xu, Y.; Kirschberg 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

A phase 1, randomized, placebo-controlle

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

✍ Eric J. Lawitz; Daniel Gruener; John M. Hill; Thomas Marbury; Lisa Moorehead; An 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 830 KB

1215 PERSISTENCE OF NS5A GS-5885 DRUG RE

1215 PERSISTENCE OF NS5A GS-5885 DRUG RESISTANCE MUTATIONS FOLLOWING 3 DAYS OF MONOTHERAPY IN GENOTYPE-1 HCV PATIENTS IS DEPENDENT ON THE HCV SUBTYPE AND SPECIFIC MUTATION

✍ Wong, K.A.; Worth, A.; Brainard, D.M.; Lawitz, E.; Miller, M.D.; Mo, H. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB